Enterprise Value

903.8M

Cash

433M

Avg Qtr Burn

-30.38M

Short % of Float

6.26%

Insider Ownership

4.78%

Institutional Own.

78.74%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 3

Update

Phase 2b

Data readout

Phase 1

Data readout

CLN-049 (FLT3xCD3) Details
Acute myeloid leukemia, Relapsed/refractory acute myeloid leukemia

Phase 1

Data readout

Phase 1

Data readout

CLN-619 (MICA/B) Details
Solid tumor/s, Cancer

Phase 1

Data readout

CLN-978 (CD19xCD3) Details
Non-Hodgkin lymphoma, Blood cancer, Cancer

Phase 1

Update

Phase 1

Initiation

CLN-978 (CD19xCD3) Details
Autoimmune disease, Systemic lupus erythematosus

IND

Submission